Cargando…
Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies
Background: Immunizations against SARS-CoV-2 virus are now available and recommended, but the effect of additional dosing of the vaccine in immunocompromised MS patients is unknown. Methods: Part I - A retrospective chart review of MS patients who were vaccinated against SARS-CoV-2 and tested commer...
Autores principales: | Wallach, Asya I., Schiebel, Matthew, Picone, Mary Ann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072817/ https://www.ncbi.nlm.nih.gov/pubmed/35636275 http://dx.doi.org/10.1016/j.msard.2022.103856 |
Ejemplares similares
-
The presence of SARS-CoV2 antibodies in MS patients
por: Wallach, Asya I., et al.
Publicado: (2021) -
Three-dose vaccination elicits neutralising antibodies against omicron
por: Wu, Mary, et al.
Publicado: (2022) -
Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
por: Maglione, Alessandro, et al.
Publicado: (2022) -
Revisiting dose-finding of monoclonal antibodies in migraine
por: Al-Hassany, Linda, et al.
Publicado: (2023) -
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
por: Bradley, Todd, et al.
Publicado: (2021)